Valuation : BrainsWay Ltd.

Market Cap 58Cr 173.7Cr 50Cr 47Cr 43Cr 80Cr 5.46TCr 80Cr 551.73Cr 214.87Cr 2.79TCr 216.92Cr 212.19Cr 8.99TCr P/E 2026 *
-
P/E 2027 * -
Enterprise Value 58Cr 173.7Cr 50Cr 47Cr 43Cr 80Cr 5.46TCr 80Cr 551.73Cr 214.87Cr 2.79TCr 216.92Cr 212.19Cr 8.99TCr EV / Sales 2026 *
8.35x
EV / Sales 2027 * 6.77x
Free-Float
90.5%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 54 13/02/2023
Chief Tech/Sci/R&D Officer 56 01/05/2006
Director of Finance/CFO 50 23/05/2023
Director TitleAgeSince
Chairman 74 01/01/2003
Director/Board Member 70 01/11/2006
Director/Board Member 56 17/06/2019
Change 5-day change 1-year change 3-year change Capi.($)
+10.37%+15.65% - - 58Cr
-0.77%-1.65%+25.01%+12.90% 23TCr
-1.70%-4.29%+3.90%-20.72% 15TCr
-1.42%-2.08%-19.73%+18.58% 13TCr
+1.67%+1.76%-55.57%-10.57% 6.8TCr
-0.13%-0.60%+10.76%+18.03% 5.17TCr
+0.52%-1.11%-17.10%-14.24% 5.02TCr
+0.56%-2.09%+17.23%+26.86% 4.23TCr
-1.07%-1.63%+36.11%+47.61% 4.06TCr
-0.87%-5.57%-17.12%+47.47% 3.31TCr
Average +0.72%-1.35%-1.83%+13.99% 8.82TCr
Weighted average by Cap. -0.66%-1.78%+1.60%+8.12%

Financials

2026 *2027 *
Net sales 6.92Cr 21Cr 5.95Cr 5.58Cr 5.11Cr 9.54Cr 653.77Cr 9.61Cr 66Cr 26Cr 334.1Cr 26Cr 25Cr 1.08TCr 8.53Cr 26Cr 7.34Cr 6.89Cr 6.3Cr 12Cr 806.67Cr 12Cr 82Cr 32Cr 412.24Cr 32Cr 31Cr 1.33TCr
Net income 1.24Cr 3.72Cr 1.07Cr 99.99L 91.48L 1.71Cr 117.06Cr 1.72Cr 12Cr 4.61Cr 60Cr 4.65Cr 4.55Cr 192.67Cr 2.1Cr 6.3Cr 1.8Cr 1.69Cr 1.55Cr 2.89Cr 198.18Cr 2.91Cr 20Cr 7.8Cr 101.28Cr 7.87Cr 7.7Cr 326.17Cr
Net Debt - -
Logo BrainsWay Ltd.
Brainsway Ltd is an Israel-based company engaged in the development and marketing of medical devices for the treatment of various neurological and psychopathological disorders. The Company primarily offers Transcranial Magnetic Stimulation (TMS) system, a medical device that enables direct non-invasive activation of deep brain structures. Its TMS system uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. TMS system is used in various clinical applications including: major depressive disorders, obsessive-compulsive disorder, smoking addiction and others various psychiatric, neurological, and addiction disorders.
Employees
-